CATALYSTChartMill • 1d ago
Protagonist Therapeutics (NASDAQ:PTGX) Eyes Breakout as High Growth Momentum BuildsPTGX blends strong technicals (9) and high growth momentum (6) with a Setup Rating of 7, nearing a breakout despite clinical-stage risks.
Why PTGX Stock advanced +1.55% Today — RQD Quant Desk Flash
$144.34 +1.55% NASDAQ • Public Delayed / 60s Snapshot
Protagonist Therapeutics Inc. (PTGX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $9.34B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
WHALE OPTIONS TUG-OF-WAR:55% Call Buyers ($2.5M)
45% PutsMax Pain: $141.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PTGX Stock advanced +1.55% Today — RQD Quant Desk Flash
Protagonist Therapeutics Inc. (PTGX) advanced +1.55% to $144.34 as options desks priced 55% call premium vs. 45% put protection around the $141 max-pain magnet. Solid 41% profit margin (-17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 81% of its 52-week range ($75.44 – $160.81) with RSI-14 at 57.9 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $2.5M in bullish call flow vs. $2.0M in put flow (Put/Call 0.82x, implied earnings swing ±6.9%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 0% gross margin and $56.1M annual free cash flow.
Live PTGX Headlines & Catalysts
CATALYSTYahoo • 2d ago
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthProtagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTYahoo • 3d ago
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
MARKET WIREYahoo • 4d ago
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026NEWARK, CA / ACCESS Newswire / October 27, 2026 / (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank conferences taking place in November 2026.8
MARKET WIRESeekingAlpha • 7d ago
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty CompounderProtagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy.
MARKET WIREYahoo • 8d ago
J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?J&J stock reclaims its 50-day SMA, but falling earnings estimates, a premium valuation and MedTech weakness raise questions about its near-term outlook.
CATALYSTBenzinga • 10d ago
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.
MARKET WIREYahoo • 11d ago
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayMarket Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare light-sensitivity disorder reported that its pivot
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live PTGX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
PTGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.36%⚡ TESTING RESISTANCE
2026-10-30O $144.3H $146.0L $142.5C $144.9VOL 322.6K
RES: $148.9SUP: $125.6SMA50: $142.9SMA200: $116.6
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PTGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
23.9%/yr Implied 5Y Growth
vs. 0.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PTGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PTGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PTGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
PTGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PTGX stock moving today?
Why PTGX Stock advanced +1.55% Today — RQD Quant Desk Flash. Solid 41% profit margin (-17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.